The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

10 Aug 2021 07:00

RNS Number : 0791I
MaxCyte, Inc.
10 August 2021
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options

Gaithersburg, Maryland - 10 August 2021: MaxCyte  (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, announces that on 9 August 2021, options of common stock in the Company ("Common Stock") were granted equally to all Company employees, including 100,000 options granted to PDMRs who are directors or officers of the Company ("PDMR Option Grants"). Details of the PDMR Option Grants are given below:

 

Grants to PDMRs

 

Doerfler, Doug

10,000

Thompson, J. Stark

10,000

Mandell, Art

10,000

Erck, Stan

10,000

Brooke, Will

10,000

Johnston, John

10,000

Douglas, Richard

10,000

Hemrajani, Rekha

10,000

Al-Wakeel, Yasir

10,000

Murphy, Amanda

10,000

Total

100,000

 

 

All option grants vest over 4 years. 1/4th of the grants vest 1 year following the date of the grant, with the remainder of the options vesting ratably monthly in 36 monthly installments thereafter. The options have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 9 August 2021, of $16.63

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Doug Doerfler

2

Reason for the notification

a)

Position/status

Chief Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

J. Stark Thompson

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Art Mandell

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Stan Erck

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Will Brooke

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

John Johnston

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Douglas

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Rekha Hemrajani

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Yasir Al-Wakeel

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Amanda Murphy

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte, Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options of Common Stock

b)

Identification Code

US57777K1060

c)

Nature of the transaction

Grant of options

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

$16.63

 

10,000 options

e)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

N/A

f)

Date of the transaction

9 August 2021

g)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

MaxCyte Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black / Duncan Monteith / Matthew O'Dowd

 

 

+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

 

 

+44 (0)20 7710 7600

 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

 ir@maxcyte.com

 

US Media Relations

Jamie Lacey-Moreira

PressComm PR, LLC

 

+1 410-299-3310

jamielacey@presscommpr.com

 

 

 

 

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAFPNELEFEAA
Date   Source Headline
24th Jan 20227:30 amRNSPreliminary Unaudited Q4 & FY 2021 Revenue Results
29th Dec 20213:30 pmRNSHoldings in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
23rd Nov 20217:32 amRNSPurchase of Common Stock
17th Nov 20215:36 pmRNSExercise of options and PDMR Dealing
11th Nov 20217:00 amRNSMaxCyte Reports Third Quarter Financial Results
3rd Nov 20211:00 pmRNSAppointment of Chairman of the Board
29th Oct 20215:01 pmRNSResult of AGM
28th Oct 20213:00 pmRNSLicense with Nkarta, Inc.
26th Oct 20217:00 amRNSNotice of Results
6th Oct 20217:00 amRNSHoldings in Company
1st Oct 20213:49 pmRNSNotice of AGM and Change of Director
1st Oct 202112:36 pmRNSTotal Voting Rights
17th Sep 20212:35 pmRNSMaxCyte Set to Join Russell 2000® Index
14th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSFiling of Form 10-Q
2nd Sep 20212:26 pmRNSNotice of Results
10th Aug 20217:00 amRNSGrant of Options
9th Aug 20217:00 amRNSLicense with Sana Biotechnology
5th Aug 20214:05 pmRNSAmendments to Bylaws
3rd Aug 20213:51 pmRNSClosing of Offering
2nd Aug 20217:00 amRNSFull Exercise of Over-Allotment Option
30th Jul 20214:43 pmRNSSecond Price Monitoring Extn
30th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSPricing of Offering and Approval to List on Nasdaq
26th Jul 202111:14 amRNSLaunch of Offering and Application to List
19th Jul 202112:30 pmRNSTermination of DI facility and transition to CDI
12th Jul 20217:00 amRNSS-1 Financial information & Directorate Change
12th Jul 20217:00 amRNSPublic Filing of Registration Statement with SEC
6th Jul 20215:36 pmRNSResult of Special Meeting
16th Jun 20217:01 amRNSPublication of Annual Report and Accounts
16th Jun 20217:00 amRNSStockholder Circular and Notice of Special Meeting
15th Jun 20217:00 amRNSMaxcyte Appoints Two New Non-Executive Directors
2nd Jun 20219:18 amRNSTotal Voting Rights
25th May 20217:00 amRNSSigning of Strategic Platform Licence
14th May 20217:00 amRNSProposed Dual-Listing on Nasdaq
13th May 20217:00 amRNSConsolidation of Trading Lines
20th Apr 20217:00 amRNSFull Year Results
15th Apr 20217:00 amRNSNotice of Full Year Results
1st Apr 20217:00 amRNSTotal Voting Rights
11th Mar 20213:01 pmRNSHolding(s) in Company
3rd Mar 20217:00 amRNSTotal Voting Rights
23rd Feb 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
17th Feb 20215:44 pmRNSGrant of Options
15th Feb 20214:32 pmRNSHolding(s) in Company
12th Feb 20211:59 pmRNSHolding(s) in Company
8th Feb 20212:59 pmRNSHolding(s) in Company
5th Feb 20219:01 amRNSPrice Monitoring Extension
4th Feb 20217:00 amRNSDirector Dealings and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.